Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(KFRC, PROT.OB, KTCC, KEY, KEYP) Stock Report from

|Includes: KEY, Kforce, Inc. (KFRC), KTCC




Kforce Inc. (Nasdaq:KFRC), a provider of professional staffing services and solutions, on Monday, November 1, 2010 will release third quarter results post-market and host a conference call to discuss the results.

The call will begin at 5:00 p.m. EST.


prot PROT, Proteonomix, Inc., PROT.OB

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

** PROT has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.

This is another step in the development of PROT’s intellectual property and getting StromaCel into the commercial market.

The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained PROT believes that the stromal cell technology will have major importance in the treatment of cardiac damage caused by heart attacks.

Recently, PROT has executed a joint venture agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).

The Investor Group assumes a variety of operational duties under the agreement, including some regulatory responsibility in the U.A.E., physician recruitment and cooperative management of the local entity. The Investor Group $5 million cash investment includes the purchase of $1 million of cellular material from PROT.

Additionally, as part of the agreement PROT will license to XGen (the joint venture), both a use and treatment license in the UAE, as well as a license to manufacture the cellular material. The agreement also anticipates the formation of treatment facilities in other locations to be jointly agreed upon between the Company and the Investor Group. Each new facility would require the Investor Group to contribute a minimum investment of $5 million.

The agreement calls for PROT, through its wholly owned subsidiary, StromaCel, Inc., to receive $ 7,500 per treated patient.

PROT has been contacted by several European entities that have requested additional information about its proprietary stem cell activities.

Mr. Michael Cohen, PROT’s Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.

More about PROT at


Key Tronic Corporation (Nasdaq:KTCC) plans to report its results for the first quarter of fiscal 2011 after market close on October 26, 2010.

KTCC will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on October 26, 2010


KeyCorp (NYSE:KEY) reported that KeyBank has signed a 10-year lease for 66,470 square feet of space on the Sprint campus located in Overland Park, Kan. for its commercial real estate loan servicing group.

The group currently occupies space in Commerce Tower, located in downtown Kansas City, and that lease expires in March 2011.


Keyuan Petrochemicals, Inc. (Nasdaq:KEYP) ("Keyuan or the "Company"), a leading merchant manufacturer of various petrochemical products in China, recently reported that the Company closed a private placement financing with institutional investors with gross proceeds of $20.3 million to fund the purchase of raw materials for its petrochemical production facility.

The lead investor was Prax Capital ("Prax"), a China-focused private equity fund that invests in KEYP through its solely owned investment vehicle Dragon State International Limited.


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).